Novo Nordisk (NVO)
(Delayed Data from NYSE)
$123.05 USD
-0.97 (-0.78%)
Updated May 3, 2024 04:00 PM ET
After-Market: $123.01 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$123.05 USD
-0.97 (-0.78%)
Updated May 3, 2024 04:00 PM ET
After-Market: $123.01 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
by Zacks Equity Research
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus
by Santanu Roy
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.
4 Large Drug Stocks to Hold on to Amid Industry Challenges
by Kinjel Shah
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
by Zacks Equity Research
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day.
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health
by Zacks Equity Research
Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health are included in this Analyst Blog.
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
Beat the Market the Zacks Way: MediaAlpha, NVIDIA, Walmart in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $124.93, denoting a +0.06% change from the preceding trading day.
Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up
by Zacks Equity Research
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond
by Neena Mishra
We discuss attractive investment opportunities within the healthcare industry.
Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
by Zacks Equity Research
Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
2 Top Biotech Buyout Candidates
by Andrew Rocco
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities